![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260922_Pharming_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Pharming<\/p>\n Event Type<\/strong><\/p>\n Clinical Data Readout<\/p>\n Modality<\/strong><\/p>\n Small Molecule<\/p>\n Asset<\/strong><\/p>\n Leniolisib<\/p>\n Target<\/strong><\/p>\n PI3K delta<\/p>\n Disease Area<\/strong><\/p>\n Genetically Defined Primary Immunodeficiencies<\/p>\n Pharming reported positive topline data from 13 participants with genetically defined primary immunodeficiencies linked to PI3K signaling. In the open label within patient dose escalation study, leniolisib produced a mean 26.4 percent spleen volume reduction and smaller index lymphoproliferative lesions, with infections the most common adverse events and no new safety signal. Detailed data will be presented at ESID in October.<\/p>\n The trial enrolled participants with variants affecting SOCS1, PTEN, CTLA4, NFKB1, FAS, NRAS or KRAS associated immune dysregulation. Dosing escalated from 10 mg twice daily to 30 mg and then 70 mg. Nine of the 13 participants also had common variable immunodeficiency.<\/p>\n Leniolisib is already approved for activated PI3K delta syndrome, where pathogenic PIK3CD or PIK3R1 variants drive lymphoproliferation and immune deficiency. The new study tests whether pathway hyperactivation downstream of other genetic lesions creates a broader pharmacologically responsive group. A separate CVID study is expected to report in the fourth quarter.<\/p>\n Interpretation one is that PI3K delta activity is a convergent node across heterogeneous immune dysregulation disorders. Reduction in spleen and lesions is consistent with pathway control. Against this, a 13 person uncontrolled basket cannot separate genotype specific effects, dose effects or natural variability, and lymphoid shrinkage does not necessarily improve infections or immune function.<\/p>\n Interpretation two is that mechanism based grouping can expand a rare disease franchise beyond one genotype. That requires a biomarker defining pathway activation and prospective evidence that benefit is reproducible within each genetic subgroup. Broad inhibition may also impair protective immunity, making infection frequency and immunoglobulin support central to benefit risk.<\/p>\n Upgrade evidence includes genotype resolved responses, improved cytopenias and infection burden, durable immune reconstitution and controlled confirmation. Heterogeneous nonresponse, worsening infections or no functional benefit would falsify broad pathway convergence.<\/p>\n Leniolisib is an oral selective PI3K delta inhibitor approved as Joenja for APDS. PI3K delta signaling controls lymphocyte activation and survival. Different genetic defects can converge on excessive signaling and cause lymphadenopathy, splenomegaly, autoimmunity and infection susceptibility, but pathway dependence and optimal inhibition may differ by genotype.<\/p>\n The signal is positive but exploratory. It supports testing pathway defined treatment across genetically diverse primary immunodeficiencies and could expand leniolisib beyond APDS. The data are not sufficient to infer a class wide responder population; genotype resolved clinical and immune outcomes are required.<\/p>\n Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: high for the disclosed topline observations. Confidence in Interpretation: moderate low because the study is small, open label and genetically heterogeneous.<\/p>\n","protected":false},"excerpt":{"rendered":" Pharming reported positive topline data from 13 participants with genetically defined primary immunodeficiencies linked to PI3K signaling. In the open label within patient dose escalation study, leniolisib produced a mean 26.4 percent spleen volume…<\/p>\n","protected":false},"author":1,"featured_media":3382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,3],"tags":[743,842,42],"class_list":["post-3363","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-therapeutic-indication","tag-leniolisib","tag-pharming","tag-primary-immunodeficiency"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3363"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3363\/revisions"}],"predecessor-version":[{"id":3392,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3363\/revisions\/3392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3382"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n